Savient cuts sales force $56m to boost Krystexxa: paradox or paralysis?
This article was originally published in Scrip
Executive Summary
Louis Ferrari, Savient Pharmaceuticals' executive vice president and president of North American commercial operations, was named president and CEO on 9 July when the company announced a 35% reduction of its workforce and realignment of its operations to support commercialization of the refractory chronic gout (RCG) therapy Krystexxa (pegloticase).